Significance of Metabolic Tumor Volume at Baseline and Reduction of Mean Standardized Uptake Value in 18F-FDG-PET/CT Imaging for Predicting Pathological Complete Response in Breast Cancers Treated with Preoperative Chemotherapy
The usefulness of 18F-fluorodeoxyglucose-positron emission tomography/computed tomography for evaluating the treatment efficacy of breast cancers is well-established; however, the predictive values of parameters such as metabolic tumor volume (MTV) and total lesion glycolysis (TLG) remain unknown.
Methods
This study examined 199 breast cancers treated with primary systemic chemotherapy (PSC) followed by operation, and determined the values of maximum standardized uptake value (SUVmax), peak SUV (SUVpeak), mean SUV (SUVmean), MTV, and TLG at baseline. Among these cases, data on early changes in these metabolic parameters in 70 breast cancers were also assessed.
Results
A pathological complete response (pCR) was achieved in 64 breast cancers. Breast cancers with low MTV at baseline had a significantly higher pCR rate than breast cancers with high MTV (47.9% vs. 23.4%; p= 0.0005). High reduction rates (∆) of SUVmax (p= 0.0001), SUVpeak (p= 0.0001), and SUVmean (p< 0.0001) resulted in an increased pCR compared with those for low ∆. The pCR rate was highest for the combination of low MTV and high ∆SUVmean (86.7%), and lowest for high MTV and low ∆SUVmean (15.4%); the remaining combinations were intermediate (58.6%; p< 0.0001). The combination of low MTV at baseline and high ∆SUVmean was a significant and independent predictor for pCR (odds ratio 28.63; 95% confidence interval 1.94–422.42; p= 0.0146) in multivariable analysis.
Conclusions
Low levels of MTV at baseline and a high reduction of SUVmean after PSC was significantly associated with pCR. These findings suggest the usefulness of these metabolic parameters for predicting the treatment efficacy of breast cancers.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Pathological complete response (pCR), defined as the lack of residual cancer after neoadjuvant chemotherapy (NAC), has been established as a surrogate marker for excellent prognosis of operable breast cancers. Small tumor size, higher tumor grade, and high proliferative activity are significant predictors for a high rate of pCR.1 However, the sensitivity and specificity of predicting pCR using these clinical factors are not high2,3 and the identification of more precise predictive factors is a critical issue.
In addition to the diagnostic ability of 18F-fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT),4 the usefulness of the maximum standardized uptake value (SUVmax) on FDG-PET for predicting the prognosis of operable breast cancers is well established.5–9 The value of SUVmax as a predictive tool for treatment efficacy was reported in metastatic10 and early breast cancers.11 In the NAC setting, a significant association between an increased SUVmax and a high rate of pCR has been reported.12,13 In addition to baseline values, changes in these values after treatment are significantly associated with the response to chemotherapy.14 Since altered glucose metabolism occurs earlier than tumor shrinkage,15 it may be possible to evaluate the treatment efficacy as early as after one or two treatment cycles.
Anzeige
SUVmax levels have been reported to be inaccurate compared with the actual uptake of FDG, due to the partial volume effect.16 Since volume-based parameters on FDG-PET, including metabolic tumor volume (MTV) and total lesion glycolysis (TLG), evaluate not only metabolic activity but also total tumor burden, recent studies have focused on these metabolic parameters rather than on SUVmax for predicting the response to chemotherapy. Although early reductions of SUVmax are reportedly associated with improved response to NAC,17,18 which metabolic parameter offers the most precise prediction remains unknown. In addition, the superiority of baseline or early response to treatment PET data is also undetermined.
The present study explored the predictive values of SUVmax, SUVpeak, SUVmean, and volume-based parameters, including MTV and TLG, at baseline in breast cancers treated with primary systemic chemotherapy (PSC). Additionally, early changes in these parameters after treatment were also investigated in terms of their relationships with treatment efficacy.
Patients and Methods
Patient Recruitment
This retrospective study constitutively recruited a total of 267 breast cancer patients who underwent surgery after preoperative chemotherapy between October 2008 and May 2018. Among these participants, 194 patients who underwent FDG-PET/CT before starting PSC were selected. Since five patients had bilateral breast cancers, we analyzed a total of 199 breast cancers in 194 patients. We evaluated response in the primary sites (breast), and nine patients with stage IV who had PSC followed by operation were also included. We also obtained FDG-PET/CT data after the start of PSC for 69 patients (70 breast cancers).
The Ethics Committee of Hyogo College of Medicine approved the present study (numbers 1818 and 1708), and written informed consent was obtained from all 69 participants who underwent FDG-PET/CT after the start of PSC (number 1708, UMIN000030408). In the remaining patients, only baseline FDG-PET/CT data from clinical practice were used and offered no risk to participants; thus, written informed consent was not required (number 1818).
Anzeige
Chemotherapy Regimen and Evaluation of Pathological Response
Preoperative chemotherapies involving anthracycline-containing, taxane-based, sequential use of anthracycline-containing and taxane, and unspecified regimens were administered in 6, 48, 137, and 3 patients, respectively. Concurrent use of trastuzumab with chemotherapy was administered to 64 patients. Pathological examinations of the whole area of pre-existing breast cancer lesions were performed, and pCR was defined as complete absence of invasive cancer cells in the breast.19
FDG-PET/CT was performed using a Gemini GXL16 or Gemini TF64 PET/CT scanner (Philips Medical Systems, Eindhoven, The Netherlands) following injection of 4.0 or 3.0 MBq/kg body weight FDG for the GXL16 and TF64, respectively. Scanning images were obtained approximately 60 min after injection, as described previously.20 The 194 patients underwent FDG-PET/CT examination before starting PSC, of whom 69 (70 breast cancers) underwent a repeat FDG-PET/CT examination after starting chemotherapy. We obtained FDG-PET/CT data after one cycle of PSC (2–3 weeks after the start of chemotherapy), except for one patient whose data were obtained after two cycles (electronic supplementary data).
Imaging Analyses
To quantify 18F-FDG uptake, the SUVs were measured. We set the volume of interest (VOI) as the area in which FDG accumulated in the breast, along the margin of tumor uptake. The SUV was calculated as the regional radioactivity concentration (Bq/mL)/[injected dose (Bq)/patient weight (g)] in the most intense area of 18F-FDG accumulation (a region of interest [ROI]). We selected the region containing the tumor in which the FDG in the breast was accumulated, as observed on the image, and set a target VOI manually in the breast cancer primary lesion with FDG accumulation. The maximum value of SUV in the VOI was defined as the SUVmax, and the volume of voxels of ≥ 40% of the SUVmax in the VOI was defined as the MTV.21–23 The SUVpeak was defined as the average activity concentration within a 1 cm3 spherical VOI centered on the ‘hottest focus’ within the primary tumor. The average SUV value in the voxel that showed ≥ 40% was defined as the SUVmean and TLG was defined as MTV × SUVmean. These parameters were all automatically calculated by the computer software package GI-PET (AZE Co., Ltd, Tokyo, Japan). Harmonization of data in different PET/CT systems was performed using phantom data.
The percentage changes (∆%) of PET data at baseline and after the start of PSC in each of the five parameters were calculated as follows: percentage change (∆%) = (delayed parameter − baseline parameter)/baseline parameter × 100.
Statistical Analysis
The associations of clinicopathological characteristics between breast cancers that achieved pCR and those that did not were analyzed using the Fisher’s exact or Wilcoxon rank-sum tests. The relationships between pCR and levels of each metabolic parameter were calculated using Fisher’s exact tests, and logistic regression was used to obtain odds ratios (ORs) and 95% confidence intervals (CIs) by univariable and multivariable analyses of clinical factors or metabolic parameters and pCR. Statistical significance was set at p< 0.05. All statistical calculations were performed using JMP Pro 13 (SAS Institute Inc., Cary, NC, USA).
Results
Relationships Between Clinicopathological Factors and Pathological Response
We defined pCR and non-pCR in 64 and 135 breast cancers, respectively. The pCR rates were significantly higher in those with small tumor size, higher nuclear grade, estrogen receptor (ER)-negative/human epidermal growth factor receptor 2 (HER2)-negative (triple-negative [TN]) and HER2-positive subtypes, high levels of Ki67, and an anthracycline and taxane regimen (electronic supplementary Table 1 and data). The SUVmax, SUVpeak, and SUVmean were significantly associated with nuclear grade and Ki67 expression levels. There were significant associations between tumor size and all parameters except SUVmax, and the subtypes were significantly associated with all parameters except TLG. Lymph node metastasis was significantly associated with MTV and TLG (electronic supplementary Table 2).
Determination of the Optimal Cut-Off Values for Pathological Complete Response (pCR) of Metabolic Parameters by PET/CT at Baseline and During Primary Systemic Chemotherapy
Representative cases of PET imaging are shown in Fig. 1. The FDG uptake detected in the left breast at baseline was diminished after one cycle of chemotherapy (Fig. 1a, b) in patients who achieved pCR; however, the uptake of FDG at baseline in the right breast remained after one cycle of chemotherapy (Fig. 1c, d). The cut-off values of SUVmax, SUVpeak, SUVmean, MTV, and TLG at baseline for pCR were determined using receiver operating characteristic (ROC) curves calculated using the Youden index for the areas under the curve (AUC) (electronic supplementary Fig. 1). Similar methods were used to determine the cut-off values of the reduction rate in each metabolic parameter for pCR (electronic supplementary Fig. 2).
Fig. 1
Representative cases of FDG accumulation in breast cancers at baseline and after the start of primary systemic chemotherapy. a Baseline and b after one treatment cycle in a case of breast cancer that achieved a pCR. c Baseline and d after one treatment cycle of a case of breast cancer that did not achieve a pCR. FDG fluorodeoxyglucose, pCR pathological complete response
×
Associations Between pCR After PSC and Each Metabolic Parameter
Breast cancers with high baseline levels of SUVmax, SUVpeak, and SUVmean had a significantly higher rate of pCR than breast cancers with low levels. However, the frequency of pCR was significantly higher for low baseline levels of MTV and TLG (electronic supplementary Fig. 3). Of these baseline parameters, MTV was the most significant predictor for pCR (47.9% vs. 23.4%; p= 0.0005).
Anzeige
Similarly, breast cancers with high reduction rates had significantly higher frequencies of pCR for ∆SUVmax, ∆SUVpeak, ∆SUVmean, and ∆TLG, but not ∆MTV, in which the significance was marginal (electronic supplementary Fig. 4). The difference in pCR rates between the two groups was most significant for the ∆SUVmean (72.2% vs. 23.5%; p < 0.0001).
Univariable and Multivariable Analyses of pCR, Including Metabolic Parameters at Baseline and During Treatment
First, we analyzed data of all 199 breast cancers, including metabolic parameters at baseline. Tumor size, nuclear grade, Ki67 expression levels, subtypes, chemotherapy regimen, and all metabolic parameters at baseline, including SUVmax, SUVpeak, SUVmean, MTV, and TLG, were significantly associated with pCR in univariable analysis (Table 1). The multivariable analyses included these clinical factors with one of the metabolic parameters. As shown in Table 1, baseline MTV was significantly associated with pCR in multivariable analysis (OR 0.30, 95% CI 0.11–0.84; p= 0.0212).
Table 1
Univariable and multivariable analyses of the clinicopathological characteristics and metabolic parameters at baseline for pathological complete response in 199 breast cancers
n
Univariable
p value
Multivariable
p value
[OR (95% CI)]
[OR (95% CI)]
Menopausal status
Premenopausal
80
1.00
Postmenopausal
119
1.59 (0.85–2.96)
0.1447
T size (cm)
≤ 2.0
43
1.00
1.00
> 2
156
0.40 (0.20–0.80)
0.0093
0.40 (0.13–1.20)
0.1024
Lymph node metastasis
Negative
104
1.00
Positive
95
0.65 (0.36–1.20)
0.1677
Nuclear grade
1
74
1.00
1.00
2 + 3
115
5.76 (2.62–12.66)
< 0.0001
3.14 (1.09–9.04)
0.0342
Ki67 expression levelsa
Low
50
1.00
1.00
High
139
9.74 (2.89–32.89)
0.0002
20.58 (1.55–237.07)
0.0219
Subtypesb
TN
48
1.00
1.00
Luminal A
31
0.04 (0.01–0.34)
0.0029
2.23 (0.08–65.78)
0.6418
Luminal B
49
0.18 (0.06–0.50)
0.0010
0.20 (0.06–0.67)
0.0114
Luminal-HER2
36
0.57 (0.23–1.41)
0.2198
1.18 (0.34–4.09)
0.7908
HER2
33
3.43 (1.32–8.91)
0.0114
5.45 (1.53–19.41)
0.0089
Chemotherapy regimen
Taxane
48
1.00
1.00
Anthracycline and taxane
142
3.26 (1.42–7.47)
0.0053
2.83 (0.92–8.77)
0.0707
SUVmaxc
Low
60
1.00
High
139
2.10 (1.04–4.24)
0.0396
Not included
SUVpeakd
Low
62
1.00
High
137
2.24 (1.11–4.51)
0.0249
Not included
SUVmeane
Low
47
1.00
High
152
2.84 (1.24–6.52)
0.0135
Not included
MTVf
Low
71
1.00
High
128
0.33 (0.18–0.62)
0.0005
0.30 (0.11–0.84)
0.0212
TLGg
Low
110
1.00
High
89
0.43 (0.23–0.81)
0.0092
Not included
OR odds ratio, CI confidence interval, TN triple-negative, ER estrogen-receptor, HER2 human epidermal growth factor receptor 2, SUVmax maximum standardized uptake value, SUVpeak peak standardized uptake value, SUVmean mean standardized uptake value, MTV metabolic tumor volume, TLG total lesion glycolysis
aLow < 20%, high ≥ 20%
bTN, ER-negative/HER2-negative; Luminal A, ER-positive/HER2-negative with Ki67 < 20%; Luminal B, ER-positive/HER2-negative with Ki67 ≥ 20%; Luminal-HER2, ER-positive/HER2-positive; HER2, ER-negative/HER2-positive
cLow < 3.664, high ≥ 3.664
dLow < 3.279, high ≥ 3.279
eLow < 1.782, high ≥ 1.782
fLow < 4.416, high ≥ 4.416
gLow < 20.138, high ≥ 20.138
Data of metabolic parameters during treatment in 70 breast cancers were further analyzed. All of ∆SUVmax, ∆SUVpeak, ∆SUVmean, and ∆TLG were significant predictive factors for pCR in the univariable analysis (Table 2). Since the association between pCR and ∆SUVmean was most significant, we performed multivariable analysis, including only ∆SUVmean as a metabolic parameter, and identified ∆SUVmean as a significant and independent factor, as shown in Table 2 (OR 8.05, 95% CI 1.45–44.80; p= 0.0173).
Table 2
Univariable and multivariable analyses of the clinicopathological characteristics and the reduction of metabolic parameters after the start of chemotherapy for pathological complete response in 70 breast cancers
n
Univariable
p value
Multivariable
p value
[OR (95% CI)]
[OR (95% CI)]
Menopausal status
Premenopausal
31
1.00
Postmenopausal
39
1.28 (0.50–3.29)
0.6110
T size (cm)
≤ 2.0
14
1.00
1.00
> 2
56
0.11 (0.02–0.53)
0.0060
0.07 (0.004–1.03)
0.0522
Lymph node metastasis
Negative
29
1.00
Positive
41
0.64 (0.24–1.66)
0.3538
Nuclear grade
1
16
1.00
1.00
2 + 3
50
11.42 (2.33–55.88)
0.0026
14.89 (1.07–207.75)
0.0446
Ki67 expression levelsa
Low
9
1.00
High
58
8.57 (1.01–72.98)
0.0493
Not calculated
Subtypesb
TN
19
1.00
1.00
Luminal A
7
Not calculated
Not calculated
Luminal B
18
0.09 (0.02–0.45)
0.0030
0.11 (0.01–0.84)
0.0335
Luminal-HER2
11
0.55 (0.12–2.56)
0.4494
0.34 (0.04–3.01)
0.3352
HER2
14
1.69 (0.34–8.40)
0.5197
0.71 (0.07–6.79)
0.7692
Chemotherapy regimen
Taxane
6
1.00
Anthracycline and taxane
63
5.50 (0.61–49.80)
0.1294
∆SUVmaxc
Low
33
1.00
High
37
7.39 (2.55–21.39)
0.0002
Not included
∆SUVpeakd
Low
33
1.00
High
37
7.39 (2.55–21.39)
0.0002
Not included
∆SUVmeane
Low
34
1.00
High
36
8.45 (2.88–24.81)
0.0001
8.05 (1.45–44.80)
0.0173
∆MTVf
Low
26
1.00
High
44
2.49 (0.91–6.79)
0.0756
Not included
∆TLGg
Low
32
1.00
High
38
6.50 (2.27–18.62)
0.0005
Not included
OR odds ratio, CI confidence interval, TN triple-negative, ER estrogen receptor, HER2 human epidermal growth factor receptor 2, SUVmax maximum standardized uptake value, SUVpeak peak standardized uptake value, SUVmean mean standardized uptake value, MTV metabolic tumor volume, TLG total lesion glycolysis, ∆ reduction rate
aLow < 20%, high ≥ 20%
bTN, ER-negative/HER2-negative; Luminal A, ER-positive/HER2-negative with Ki67 < 20%; Luminal B, ER-positive/HER2-negative with Ki67 ≥ 20%; Luminal-HER2, ER-positive/HER2-positive; HER2, ER-negative/HER2-positive
cLow < − 56.3, high ≥ − 56.3
dLow < − 55.1, high ≥ − 55.1
eLow < − 55.8, high ≥ − 55.8
fLow < − 22.2, high ≥ − 22.2
gLow < − 65.0, high ≥ − 65.0
Predictive Ability of pCR for the Combination of Baseline Metabolic Tumor Volume (MTV) and ∆SUVmean Parameters
Since both baseline MTV and ∆SUVmean were significantly associated with pCR, we further analyzed the combination of these parameters. The pCR rate was highest for low baseline MTV and high ∆SUVmean (86.7%), and lowest for high baseline MTV and low ∆SUVmean (15.4%) [Fig. 2a]. Since breast cancers with high baseline MTV and high ∆SUVmean, as well as those with low baseline MTV and low ∆SUVmean, showed intermediate pCR rates (61.9% and 50%, respectively), we further combined these two intermediate groups in Fig. 2b (pCR rate 58.6%). In multivariable analysis, the combination of baseline MTV and ∆SUVmean was a significant and independent predictor of pCR (OR 28.63, 95% CI 1.94–422.42; p= 0.0146 for low baseline MTV and high ∆SUVmean) (Table 3).
Fig. 2
pCR rates according to the combination of MTV at baseline and ∆SUVmean. The pCR rates of a four groups and b three groups after combining both high and both low MTV and ∆SUVmean. pCR pathological complete response, MTV metabolic tumor volume, SUVmean mean standardized uptake value, H high, L low, ∆ reduction rate
Table 3
Univariable and multivariable analyses of the clinicopathological characteristics and the combination of MTV at baseline with the reduction of SUVmean in 70 breast cancers
n
Univariable analysis
p value
Multivariable analysisa
p value
[OR (95% CI)]
[OR (95% CI)]
MTVb
Low
47
1.00
1.00
High
23
0.20 (0.07–0.60)
0.0043
0.18 (0.03–1.19)
0.0749
∆SUVmeanc
Low
34
1.00
High
36
8.45 (2.88–24.81)
0.0001
8.05 (1.45–44.80)
0.0173
MTV and ∆SUVmean
High and low
26
1.00
1.00
Both high, or both low
29
7.79 (2.13–28.49)
0.0019
6.89 (1.10–43.24)
0.0394
Low and high
15
35.75 (5.73–223.00)
0.0001
28.63 (1.94–422.42)
0.0146
MTV metabolic tumor volume, SUVmean mean standardized uptake value, OR odds ratio, CI confidence interval, pCR pathological complete response, ∆ reduction rate
aAdjusted for tumor size, nuclear grade, and subtypes that were significantly associated with pCR by univariable analysis in Table 2
bLow < 4.416, high ≥ 4.416
cLow < − 55.8, high ≥ − 55.8
×
Anzeige
Discussion
The results of the present study demonstrated that low levels of baseline MTV and early reduction of SUVmean after the start of treatment were significant and independent predictive factors for a higher rate of pCR in breast cancers treated with PSC. The combination of both parameters predicts pCR more precisely compared with that of baseline MTV or ∆SUVmean alone. The SUVmax was a significant predictor of pCR after NAC in 273 breast cancers (OR per one-unit increase 1.09, 95% CI 1.02–1.16; p= 0.008).24 However, consistent with our study, SUVmax, SUVpeak, and SUVmean at baseline were not associated with pathological response in previous studies.21,25–29 Contrary to SUVs, MTV is a volume-based metabolic parameter that represents both metabolic activity and total tumor burden in each tumor. However, Cho et al. reported no significant association between pCR and baseline TLG or MTV values.27 Although Cheng et al. reported no correlation between TLG and pCR,21 baseline MTV was marginally associated with pCR in the HER2-negative group (n= 30; p= 0.081). The reason for this discrepancy may be the smaller number of participants (n= 26 and n= 30) compared with our study (n= 199).
Although SUVmax levels at baseline and after one cycle were not correlated with pCR in 50 TN breast cancers, higher ∆SUVmax values were significantly associated with increased pCR in multivariable analysis (OR 7.1; p= 0.014).30 Similarly, early changes in SUVmax corrected for lean body mass (SULmax) values between those achieving pCR and those not achieving pCR differed significantly in 59 HER2-negative breast cancers (63.0% vs. 32.9%; p= 0.003).31 Further studies demonstrated that not at baseline, but rather ∆SUVmax after the start of NAC, was significantly associated with pCR.25,28,29,32,33 In addition, the mean percentage of ∆TLG30% (p= 0.005), but not ∆MTV30% (p= 0.262), was significantly greater in the pCR group27; however, neither ∆TLG nor ∆MTV were significantly associated with pCR in the report by Cheng et al.21 Despite the significant correlation between tumor size reduction rate and the reduction rates of MTV (p= 0.0004) or TLG (p= 0.002), but not SUVmax (p= 0.07),34 the ∆MTV and ∆TLG might be less useful than ∆SUVmax when considering their pCR predicting ability.
Groheux et al. reported the AUC of pCR prediction increased from 0.63 to 0.76 when combined ∆SUVmax with genomic grade index (GGI; p= 0.016) in TN breast cancer patients.28 We identified the significance of the combination of baseline MTV and ∆SUVmean in terms of pCR prediction. Interestingly, MTV was significantly associated with tumor size, but not with grade. Conversely, SUVmax was significantly associated with grade, but not with tumor size.33 Thus, MTV and ∆SUV may be a useful combination for predicting pCR mediating through different mechanisms. Small metabolic tumor size evaluable by MTV and high reduction rate of metabolic activity evaluable by SUVmean may be linked to achieving a pCR. We obtained data regarding metabolic parameters after treatment in 22 breast cancers; all six breast cancers that retained FDG uptake had non-pCR. Even though FDG uptake diminished after treatment, 5 of 16 (31.3%) breast cancers were defined as non-pCR (electronic supplementary data). Thus, the data obtained after treatment may not improve the ability to predict pCR.
We set the optimal cut-off values of ∆SUVmax, ∆SUVpeak, and ∆SUVmean at 56.3%, 55.1%, and 55.8%, respectively, and the predictive values of these metabolic parameters were similar. Previous studies reported ∆SUVmax cut-off values ranging from 50 to 82.2%.35 In addition, we used the average SUV value in the voxel that showed ≥ 40% of SUVmax as the SUVmean, as used in previous studies.21–23 In other studies, thresholds of VOI were set to values between 30 and 50%.27 Although the best threshold was unknown, we obtained similar results when calculated with other cut-off values and the reproducibility of SUVmean measurement was confirmed by a coauthor (data not shown). Issues regarding which parameter of SUV is most useful, and the best optimal cut-off value or threshold, require confirmation in future studies. In addition, we concluded, based on 70 breast cancers, that the sample size was not enough. Further studies involving large numbers of participants are needed. To our knowledge, this is the first study to demonstrate the useful combination of metabolic parameters obtained by PET for pCR in breast cancers treated with preoperative chemotherapy.
Anzeige
Conclusions
The combination of baseline MTV and ∆SUVmean precisely predicted the pCR in breast cancers treated with chemotherapy. The predictive value of this combination was independent and strong compared with that of other clinical factors, including tumor size, tumor grade, Ki67 levels, and subtypes. Small metabolic tumor size evaluable by MTV, and a high metabolic activity reduction as determined by SUVmean, might be useful for predicting improved pCR in breast cancers treated with preoperative chemotherapy.
Disclosure
Tomoko Higuchi, Yukie Fujimoto, Hiromi Ozawa, Ayako Bun, Reiko Fukui, Yoshimasa Miyagawa, Michiko Imamura, Kazuhiro Kitajima, Koichiro Yamakado, and Yasuo Miyoshi declare that they have no competing interests.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Mit der Zeitschrift Die Chirurgie erhalten Sie zusätzlich Online-Zugriff auf weitere 43 chirurgische Fachzeitschriften, CME-Fortbildungen, Webinare, Vorbereitungskursen zur Facharztprüfung und die digitale Enzyklopädie e.Medpedia.
Bis 30. April 2024 bestellen und im ersten Jahr nur 199 € zahlen!
Significance of Metabolic Tumor Volume at Baseline and Reduction of Mean Standardized Uptake Value in 18F-FDG-PET/CT Imaging for Predicting Pathological Complete Response in Breast Cancers Treated with Preoperative Chemotherapy
Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.
Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.
